Urodynamix and Laborie Medical Technologies Announce Worldwide Distribution Agreement

VANCOUVER, British Columbia, May 17, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) announced today that it has entered into a worldwide distribution agreement with Laborie Medical Technologies (“Laborie”), the world leader in urodynamics systems and pelvic-floor diagnostic devices. The agreement grants Laborie non-exclusive sales, marketing and distribution rights for Urodynamix’s URO-NIRS Bladder Monitor in North America and Europe, and exclusive sales, marketing and distribution rights in South America, the Middle East and Asia.

Under the terms of the agreement, Laborie will pay an upfront licensing fee, milestone payments, guarantee minimum sales quantities, and fund individual clinical trials to be carried out by Urodynamix in North America, South America, Middle East and Asia territories as part of Laborie’s sales and marketing commitment in each region. Specific financial terms and other details of the agreement were not disclosed.

“Our NIRS-based diagnostic system represents a breakthrough in urodynamics testing and creates an untapped new market in urinary incontinence and prostate disease,” said Urodynamix CEO Barry Allen. “Laborie has the largest and most knowledgeable urodynamics equipment sales force in the world and the enthusiasm and ability to effectively market our product within these regions. This partnership with Laborie is consistent with our strategy to maximize shareholder value by accelerating sales penetration and minimizing costs by working with existing specialized sales forces.”

“We have shown ourselves to be the market leader in urodynamics equipment and our sales force is well positioned to introduce and promote this exciting technology,” said Ing Goping, CEO of Laborie. “Leveraging Urodynamix’s NIRS technology with Laborie’s unique UDS™ platform will allow us to penetrate these large and growing markets. This agreement is consistent with our strategy to introduce the latest advances in technology, and improve medical care and quality of life for people with voiding disorders.”

About Laborie Medical Technologies

Founded in 1982 by Ray Laborie, a Canadian medical device specialist, Laborie Medical Technologies is the leading global manufacturer of urodynamics equipment used in the diagnosis and treatment of incontinence. Laborie’s product line consists of the industry’s most advanced urodynamics and biofeedback/stimulation systems, patient management software, catheters and disposables. In addition to utilizing the latest advances in technology, Laborie produces and sponsors leading educational courses in urodynamics for doctors, nurses and technicians around the world each year.

Laborie introduced the first computerized Urodynamics (UDS™) processor in 1984, and now claims the largest and most knowledgeable UDS sales force in the world with offices in Ontario, Quebec, Vermont, Belgium and China, and direct sales and distribution networks in 52 countries across North America, Europe and Asia. In addition to an extensive sales force, Laborie’s team of over 30 on-staff engineers, field technicians and UDS nurses install UDS systems, train users, and work in concert with leading clinician-researchers and local universities. These resources ensure that Laborie can bring the talent and technical knowledge necessary to assure that its products incorporate the most recent advancements and also reflect the practical realities of the typical urology or urogynecology clinic.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company’s disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Craig Pamplin, PhD, CFA

Director, Corporate Development and Communications

Urodynamix Technologies Ltd.

Tel: (604) 638-0247

Email: cpamplin@urodynamix.com

www.urodynamix.com

Ing Goping

Chief Executive Officer

Laborie Medical Technologies

Tel: (802) 857-1300

Email: igoping@laborie.com

www.laborie.com